Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

Lancet

Volumn 354, Issue 9184, 1999, Pages 1112-1115

  Brinkman, Kees ^a   Smeitink, Jan A ^d   Romijn, Johannes A ^b   Reiss, Peter ^c  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

LIPODYSTROPHY; MITOCHONDRION; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033604038     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)06102-4     Document Type: Note

References (34)

1. Lo J.C., Mulligan K., Tai V.W., Algren H., Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 351:1998;867-870.
2. Roth V.R., Kravcik S., Angel J.B. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 27:1998;65-67.
3. Gervasoni C., Ridolfo A.L., Trifiry G.et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 13:1999;465-471.
4. Miller K.D., Jones E., Yanovski J.A., Shankar R., Feuerstein I., Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 351:1998;871-875.
5. Carr A., Samaras K., Burton S.et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;51-58.
6. Arner P. Not all fat is alike. Lancet. 351:1998;1301-1302.
7. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
8. Lenhard J.M., Weiel J.E., Paulik M.A., Lehmann J.M., Koszalka G., Furfine E.S. Indinavir enhances retinoic acid signaling: nelfinafir, saquinavir, and ritonavir inhibit retinoid effects in vitro. 6th Conference on Retroviruses and Opportunistic Infections. 1999;. abstr 665.
9. Madge S., Kinloch de Loes S., Mercey D., Johnson M.A., Weller I.V.D. Lipodystrophy in patients naive to protease inhibitors. AIDS. 13:1999;735-737.
10. Hengel R.L., Watts N.B., Lennox J.L. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 350:1997;1596.
11. Teplitsky V., Halabe A. Fat distribution in AIDS. N Engl J Med. 340:1999;969-970.
12. Enzi G. Multiple symmetric lipomatosis: an updated clinical report. Medicine. 63:1984;56-64.
13. Enzi G., Inelmen E., Baritussio A., Dorigo P., Prosdocimi M., Mazzoleni F. Multiple symmetric lipomatosis. A defect in adrenergic-stimulated lipolysis. J Clin Invest. 60:1977;1221-1229.
14. Berkovic S.F., Andermann F., Shoubridge E.A.et al. Mitochondrial dysfunction in multiple symmetrical lipomatosis. Ann Neurol. 29:1991;566-569.
15. Larsson N.G., Tulinius M.H., Holme E.et al. Segregation and manifestations of the mtDNA tRNA(Lys)A→G(8344) mutation of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 51:1992;1201-1212.
16. Silvestri G., Ciafaloni E., Santorelli F.M.et al. Clinical features associated with the A→G transition at nucleotide 8344 of mtDNA ("MERRF mutation"). Neurology. 43:1993;1200-1206.
17. Klopstock T., Naumann M., Scchalke B.et al. Multiple symmetric lipomatosis: abnormalities in complex IV and multiple deletions in mitochondrial DNA. Neurology. 44:1994;862-866.
18. Campos Y., Mártin M.A., Navarro C., Gordo P., Arenas J. Single large-scale mitochondrial DNA deletion in a patient with mitochondrial myopathy associated with multiple symmetric lipomatosis. Neurology. 47:1996;1012-1014.
19. Becker-Wegerich P., Steuber M., Olbrisch R., Ruzicka T., Auburger G., Hofhaus G. Defects of mitochondrial respiratory chain in multiple symmetric lipomatosis. Arch Dermatol Res. 290:1998;652-655.
20. Nedergaard J., Lindberg O. The brown fat cell. Int Rev Cytol. 74:1982;187-286.
21. Zancanaro C., Sbarbati A., Morroni M.et al. Multiple symmetric lipomatosis. Ultrastructural investigation of the tissue and preadipocytes in primary culture. Lab Invest. 63:1990;253-258.
22. Lewis W., Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat Med. 1:1995;417-422.
23. Brinkman K., ter Hofstede H.J.M., Burger D.M., Smeitink J.A., Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 12:1998;1735-1744.
24. Dalakas M.C., Illa I., Pezeshkpour G.H.et al. Mitochondrial myopathy caused by long-term zidovudine toxicity. N Engl J Med. 322:1990;1098-1105.
25. Arnaudo E., Dalakas M., Shanske S., Moraes C.T., DiMauro S., Schon E.A. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 337:1991;508-510.
26. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 353:1999;2093-2099.
27. Gisolf EH, de Wolf F, Pelgrom J, et al. Treatment of ritonavir (RTV)/saquinavir(SQV) versus RTV/SQV/stavudine(d4T) (the Prometheus study): preliminary results. 12th World AIDS Conference, Geneva, 1998; abstr 291.
28. Carr A., Miller J., Law M., Cooper D.A. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: a contribution to PI-treated LD syndrome. Antiviral Ther. 4:1999;19-20. (suppl 2).
29. Mallal S., John M., Moore C., James I., Mckinnon E. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection. Antiviral Ther. 4:1999;28-29. (suppl 2).
30. Viard J.P., Rakotoambinina B. Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a protease inhibitor. Antiviral Ther. 4:1999;32-33. (suppl 2).
31. Mercié P., Malvy D., Daucourt V.et al. Case report of lipodystrophy observations in patients naive of protease inhibitor treatment, Acquitaine cohort, 1999. Antiviral Ther. 4:1999;27-28. (suppl 2).
32. Galli M., Ridolfo A.L., Gervasoni C., Ravasio L., Adorni F., Moroni M. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations. Antiviral Ther. 4:1999;29. (suppl 2).
33. Saint-Marc T., Partisani M., Poizot-Martin I.et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 13:1999;1659-1667.
34. Saint-Marc T., Touraine J.L. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy. Antiviral Ther. 4:1999;31. (suppl 2).